Buy Full Version
"Antihypertensive Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Antihypertensive Market by Therapeutics (Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta Blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors, Vasodilators) - Global Opportunity Analysis and Industry Forecast, 2019-2026

Healthcare	A00436	Pages: NA	Jan 2020 \| 4462 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Antihypertensives are the drugs that are used to treat high blood pressure. Increase in blood pressure is measured in terms of systolic and diastolic blood pressure exerted by blood on the wall of artery and hence it is also termed as arterial hypertension. Antihypertensive drugs alleviate the complications of stroke and myocardial infarction. Reduction in blood pressure minimizes the risk of heart failure, ischaemic heart diseases, dementia and mortality due to hypertension. Changes in lifestyle are the prime factors that increase the number hypertensive cases. A complete analysis of the global antihypertensives market provides various aspects of market research such as market trends, market drivers, restrains and opportunities. In-depth segmental analysis helps to understand the market dynamics and would be beneficial to professionals in their decision making. The competitive landscape section focuses on key leaders within the global antihypertensives market and their major growth strategies.

Global antihypertensives market is driven by increased epidemic proportion of hypertension around the world. Changes in lifestyle, food habits and augmented stress levels have largely responsible to increase the number of hypertensive people. The global antihypertensive market is expected to show steady growth during the forecast period due to patent expiration of major antihypertensive drugs. The market could also face the challenges due to increased threat of genericization and growing competition. A steady increase in pulmonary arterial hypertension and use of fixed dose combination therapies is expected to drive the future growth of antihypertensives market. Launch of novel drug therapies with improved safety and efficacy could also boost the market growth in the near future.

Global Antihypertensives Market by Therapeutics

The global antihypertensives market is segmented by therapeutics into different categories such as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators. Diuretics hold the largest market share for antihypertensives, as it is the first line of treatment for hypertension recommended by most of the physicians. However, selection and suitability of drug candidate is based on patient’s medical history and current symptoms. Beta blocker, Calcium channel blocker ad ACE inhibitors are also a popular drug class form antihypertensives and used as first line of treatment in some cases.

Global Antihypertensives Market by Geography

Geographically, global antihypertensives market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe dominates the global antihypertensives market. Europe has high prevalence of hypertension, which is the primary cause of mortality and disability amongst people. Also in US, blood pressure is one of the major factors that has high mortality rate. Asia-Pacific is the lucrative geographic segment for antihypertensive drug manufacturers due to high incidences of cardiovascular diseases, government support and improving healthcare conditions.

Competitive Landscape

Pfizer Inc., Novartis AG, Sanofi S.A., Merck & Co., Boehringer Ingelheim, Lupin Limited, Johnson & Johnson Ltd., Astra Zeneca Plc, Daiichi Sankyo Company Limited and Ranbaxy Laboratories Limited, Inc. are some of the key players of global antihypertensives market. Over the past few years, the patent expiration of major brands, namely Revatio, Diovan, Exforge and Avapro has led to high genericization of antihypertensives market. The novel antihypertensive drugs, which are in pipeline research, are expected to partly regain the losses due to patent expiration. These novel therapies include Actos, Macitentan, Riociguat, SPP635, ACT-293987, LCZ696 and others.

High Level Analysis

A comprehensive analysis of the global antihypertensives market provides an overview of the market and its key concerns. The market segmentation section provides a deep-dive analysis of Therapeutics and geography segments, which would be helpful in understanding niche market trends. Market dynamics include market drivers, restraints and opportunities, which would help to simplify and better understand market behavior. Porter’s Five Forces analysis would be helpful to strategists to determine market profitability. Genericization of the drugs has introduced the cheaper versions of original brands and offered the cost effectiveness to the buyers. This factor strengthens the buyer’s power. Patent expiration of blockbuster drugs has offered an opportunity for local players to enter the market, which has also contributed to make the industrial rivalry intense.

KEY BENEFITS

This report offers the following benefits in particular:
Comprehensive coverage of global antihypertensives market along with disease overview, market trends, drivers and restraints would provide key insights to market dynamics
Thorough attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players
Explicit information on current clinical trials and R&D activities would be beneficial to understand the future market trends
Insightful analysis of different segments helps to recognize and capitalize future opportunities within global antihypertensives market

KEY DELIVERABLES

The global antihypertensives market is segmented into two major categories such as therapeutics and Geography.

MARKET BY THERAPEUTICS

Diuretics
Angiotensin receptor blockers (ARBs)
Angiotensin converting enzyme (ACE) inhibitors
Beta blockers
Alpha blockers
Calcium channel blockers
Renin inhibitors
Vasodilators

MARKET BY GEOGRAPHY

North America
Europe
Asia-Pacific
LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING/MARKET SHARE ANALYSIS, 2017
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities

CHAPTER 4 ANTIHYPERTENSIVE THERAPEUTICS MARKET, BY THERAPEUTICS

4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. DIURETICS
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Hydrochlorothiazide
4.2.2.1.1. Market size and forecast
4.2.2.2. Indapamide
4.2.2.2.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by type
4.4.2.1. Captopril
4.4.2.1.1. Market size and forecast
4.4.2.2. Lisinopril
4.4.2.2.1. Market size and forecast
4.4.2.3. Perindopril
4.4.2.3.1. Market size and forecast
4.4.3. Market size and forecast, by region
4.4.4. Market analysis, by country
4.5. BETA BLOCKERS
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by type
4.5.2.1. Atenolol
4.5.2.1.1. Market size and forecast
4.5.2.2. Propranolol
4.5.2.2.1. Market size and forecast
4.5.3. Market size and forecast, by region
4.5.4. Market analysis, by country
4.6. ALPHA BLOCKERS
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by type
4.6.2.1. Clonidine
4.6.2.1.1. Market size and forecast
4.6.2.2. Guanabenz
4.6.2.2.1. Market size and forecast
4.6.3. Market size and forecast, by region
4.6.4. Market analysis, by country
4.7. CALCIUM CHANNEL BLOCKERS
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. RENIN INHIBITORS
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. VASODILATORS
4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country
4.10. OTHERS
4.10.1. Key market trends, growth factors and opportunities
4.10.2. Market size and forecast, by region
4.10.3. Market analysis, by country

CHAPTER 5 ANTIHYPERTENSIVE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. PHARMACIES & DRUG STORES
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. E-COMMERCE
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. OTHERS
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6 ANTIHYPERTENSIVE THERAPEUTICS MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America antihypertensive therapeutics market, by country
6.2.2.1. U.S. antihypertensive therapeutics market
6.2.2.1.1. U.S. market, by therapeutics
6.2.2.1.2. U.S. market, by distribution channel
6.2.2.2. Canada antihypertensive therapeutics market
6.2.2.2.1. Canada market, by therapeutics
6.2.2.2.2. Canada market, by distribution channel
6.2.2.3. Mexico antihypertensive therapeutics market
6.2.2.3.1. Mexico market, by therapeutics
6.2.2.3.2. Mexico market, by distribution channel
6.2.3. North America antihypertensive therapeutics market, by therapeutics
6.2.4. North America antihypertensive therapeutics market, by distribution channel
6.3. EUROPE
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe antihypertensive therapeutics market, by country
6.3.2.1. Germany antihypertensive therapeutics market
6.3.2.1.1. Germany market, by therapeutics
6.3.2.1.2. Germany market, by distribution channel
6.3.2.2. France antihypertensive therapeutics market
6.3.2.2.1. France market, by therapeutics
6.3.2.2.2. France market, by distribution channel
6.3.2.3. UK antihypertensive therapeutics market
6.3.2.3.1. UK market, by therapeutics
6.3.2.3.2. UK market, by distribution channel
6.3.2.4. Italy antihypertensive therapeutics market
6.3.2.4.1. Italy market, by therapeutics
6.3.2.4.2. Italy market, by distribution channel
6.3.2.5. Spain antihypertensive therapeutics market
6.3.2.5.1. Spain market, by therapeutics
6.3.2.5.2. Spain market, by distribution channel
6.3.2.6. Rest of Europe antihypertensive therapeutics market
6.3.2.6.1. Rest of Europe market, by therapeutics
6.3.2.6.2. Rest of Europe market, by distribution channel
6.3.3. Europe antihypertensive therapeutics market, by therapeutics
6.3.4. Europe antihypertensive therapeutics market, by distribution channel
6.4. ASIA-PACIFIC
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific antihypertensive therapeutics market, by country
6.4.2.1. Japan antihypertensive therapeutics market
6.4.2.1.1. Japan market, by therapeutics
6.4.2.1.2. Japan market, by distribution channel
6.4.2.2. China antihypertensive therapeutics market
6.4.2.2.1. China market, by therapeutics
6.4.2.2.2. China market, by distribution channel
6.4.2.3. Australia antihypertensive therapeutics market
6.4.2.3.1. Australia market, by therapeutics
6.4.2.3.2. Australia market, by distribution channel
6.4.2.4. India antihypertensive therapeutics market
6.4.2.4.1. India market, by therapeutics
6.4.2.4.2. India market, by distribution channel
6.4.2.5. South Korea antihypertensive therapeutics market
6.4.2.5.1. South Korea market, by therapeutics
6.4.2.5.2. South Korea market, by distribution channel
6.4.2.6. Rest of Asia-Pacific antihypertensive therapeutics market
6.4.2.6.1. Rest of Asia-Pacific market, by therapeutics
6.4.2.6.2. Rest of Asia-Pacific market, by distribution channel
6.4.3. Asia-Pacific antihypertensive therapeutics market, by therapeutics
6.4.4. Asia-Pacific antihypertensive therapeutics market, by distribution channel
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA antihypertensive therapeutics market, by country
6.5.2.1. Brazil antihypertensive therapeutics market
6.5.2.1.1. Brazil market, by therapeutics
6.5.2.1.2. Brazil market, by distribution channel
6.5.2.2. Saudi Arabia antihypertensive therapeutics market
6.5.2.2.1. Saudi Arabia market, by therapeutics
6.5.2.2.2. Saudi Arabia market, by distribution channel
6.5.2.3. South Africa antihypertensive therapeutics market
6.5.2.3.1. South Africa market, by therapeutics
6.5.2.3.2. South Africa market, by distribution channel
6.5.2.4. Rest of LAMEA antihypertensive therapeutics market
6.5.2.4.1. Rest of LAMEA market, by therapeutics
6.5.2.4.2. Rest of LAMEA market, by distribution channel
6.5.3. LAMEA antihypertensive therapeutics market, by therapeutics
6.5.4. LAMEA antihypertensive therapeutics market, by distribution channel

CHAPTER 7 COMPANY PROFILES

7.1. NOVARTIS AG
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. PFIZER INC.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. JOHNSON & JOHNSON
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. DAIICHI SANKYO COMPANY LIMITED
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. MERCK & COMPANY, INC.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. ASTRAZENECA PLC.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. LUPIN LIMITED
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. BAYER AG
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,041 Data Pack/Excel ~~$3,840~~ $3,379 Single User License ~~$5,370~~ $4,726 Five User License ~~$6,450~~ $5,676 Enterprise User License ~~$8,995~~ $7,916

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com